Bioassociate Consulting
Long/short equity, value, event-driven, long only

BioLine Is Approaching Its Moment Of Truth

BioLineRx (NASDAQ:BLRX) is about to face one of its defining moments in 1Q 2013, when results of an interim analysis from the phase 2/3 CLARITY study of BL-1020 are expected to be released. BL-1020, BioLine's leading drug candidate, is an orally available GABA-enhanced antipsychotic for the treatment of both the positive an...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
WITH SEEKING ALPHA PRO, INVESTORS CAN ALSO:
  • Access Top Ideas, chosen by Seeking Alpha’s editors
  • Filter long and short ideas by market cap and sector
  • Get Coverage of over 5,000 stocks, many of which have little or no coverage elsewhere
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO." Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else." Patrick Rice, Mainstay Capital Management
100% Satisfaction Guaranteed
You are protected by the Seeking Alpha Money Back Guarantee and will get a prompt refund on the unused portion of your subscription at any time, for any reason.